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Background and Objective. Hematopoietic stem
cells are being increasingly used for treatment of
malignant and nonmalignant disorders. Various
attempts have been made in recent years to expand
and manipulate these cells in order to increase their
therapeutic potential. A Working Group on Hemato-
poietic Cells has analyzed the most recent advances
in this field.
Evidence and Information Sources. The method used
for preparing this review was an informal consensus
development. Members of the Working Group met
three times, and the participants at these meetings
examined a list of problems previously prepared by
the chairman. They discussed the single points in
order to achieve an agreement on different judg-
ments, and eventually approved the final manuscript.
Some authors of the present review have been work-
ing in the field of stem cell biology, processing and
transplantation, and have contributed original papers
in peer-reviewed journals. In addition, the material
examined in the present review includes articles and
abstracts published in journals covered by the Sci-
ence Citation Index® and Medline®.
State of Art. Over the last decade,  recombinant DNA
technology has allowed the large scale production of
cytokines controlling the proliferation and differenti-
ation of hemo-lymphopoietic cells. Thus, in principle,
ex vivo manipulation of hemopoiesis has become fea-
sible. The present review covers three major area of
interest in experimental and clinical hematology:
manipulation of hematopoietic stem/progenitor
cells, cytotoxic effector cells and antigen presenting
dendritic cells. Preliminary data demonstrate the
possibility of using, in a clinical setting, ex vivo
expanded hematopoietic cells with the aim of reduc-
ing, and perhaps abrogating, the myelosuppression
after high-dose chemotherapy. Concurrently, other
important potential applications for ex vivo manipu-
lation of hematopoietic cells have recently been
investigated such as the generation and expansion
of cytotoxic cells for cancer immunotherapy, and the
large scale production of professional antigen pre-
senting cells capable of initiating the process of
immune response.
Conclusions and Perspectives. Present and future
challenges in this field are represented by the expan-
sion of true human stem cells without maturation, to
extend this strategy to allogeneic stem cell trans-
plantation as well as  the manipulation of cycling of
primitive progenitors for gene therapy programs. The
selective outgrowth of normal progenitor cells over
neoplastic cells to achieve tumor-free autografts
may ameliorate the results of autologous transplan-
tation. The selective production of cellular subsets
to manipulate the graft versus-host and graft versus-
tumor effects and anti-tumor vaccination strategies
may be important  to improve  cellular adoptive im-
munotherapy.
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Hematopoietic stem cells
Following the discovery that bone marrow trans-
plantation could be used to rescue irradiated mice,
the identification and characterization of the
hematopoietic stem cell has become essential in
order to achieve new developments in stem cell
expansion and transplantation (SCT).1 The potential
for using stem cells as vehicles for gene therapy has
further increased the efforts of a number of research
groups working on stem cell identification, charac-
terization, cloning and manipulation.2
Self-renewal and differentiation 
Marrow and blood hematopoietic cells are het-
erogeneous and belong to different lineages at dif-
ferent stages of maturity. The structural and func-
tional integrity of the hematopoietic system is main-
tained by stem cells that, by definition, comprise a
relatively small cell population, located mainly in the
bone marrow, which can (i) undergo self-renewal to
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produce stem cells or (ii) differentiate to produce
progeny which is progressively unable to self-renew,
irreversibly committed to one or other of the various
hematopoietic lineages, and able to generate clones
of up to 105 lineage-restricted cells that mature into
specialized cells.3 Although in recent years, (i) the
development of in vitro and in vivo assays for hemato-
poiesis, (ii) the identification and characterization of
hematopoietic growth factors, and (iii) the develop-
ment of strategies for enriching hematopoietic cells
have expanded our knowledge and understanding of
hematopoiesis, the definition of the stem cell, origi-
nally proposed by Lajtha4 and McCulloch,5 has not
substantially changed.
In addition to self-renewal and differentiation, a
number of properties are ascribed to hematopoietic
stem cells, including a high migratory potential, the
ability to undergo asymmetric cell divisions, the
capacity to exist in a mitotically quiescent form and
extensively regenerate the different cell types that con-
stitute the tissue in which they exist.6
The issues of asymmetrical and symmetrical cell
divisions and the regulation of self-renewal/differen-
tiation process are crucial when analyzing stem cell
behavior and the potential for stem cell manipula-
tion. Asymmetric cell divisions produce one differen-
tiated daughter (progenitor cell) and another daugh-
ter that is still a stem cell (Figure 1A). When all cell
divisions are necessarily asymmetric and controlled
by cell-intrinsic mechanisms, no amplification of the
stem cell size is possible.7 Asymmetric divisions are
referred to unequally distributed transcription fac-
tors in daughter cells,8,9 and have been shown to be
possible in hematopoietic progenitors by clone-split-
ting experiments.10 Symmetric cell divisions produce
either two progenitor cells or two stem cells accord-
ing to a 0.5 probability of self-renewing versus differ-
entiative divisions (Figure 1B). In this case, it can be
assumed that the size of the stem cell pool can be
modified by factors affecting the 0.5 probability val-
ue, i.e., factors that control the probability of self-
renewing versus differentiative divisions.7 A third
model postulates that individual cell divisions can
be, but not necessarily are, asymmetric with respect
to daughter cell fate (Figure 1C). This model also
implies that daughters behave differently due to dif-
ferent local environments. Although it is not known
whether a single cell can switch from an asymmetric
to a symmetric mode of cell division, available evi-
dence in the hematopoietic stem cell system favors a
predominance of symmetric cell divisions.    
The decision of a stem cell to either self-renew or
differentiate as well as the selection of a specific dif-
ferentiation lineage by a multipotent progenitor dur-
ing commitment have been proposed to be regulat-
ed according to either stochastic or deterministic
(inductive) models. Based on computer simulation
and the distributions of colony-forming units in
spleen (CFU-S) in individual spleen colonies, sto-
chastic models postulate that the decision of a stem
cell to self-renew (birth) or to differentiate (death) is
randomly regulated by a probability parameter "p"
which is equal to 0.5 in steady-state conditions.11
Deterministic models postulate the existence of lin-
eage-specific anatomic niches that direct the differ-
entiation of uncommitted progenitors.12 There is
experimental evidence suggesting that the hemato-
poietic system may employ both stochastic and
deterministic strategies, probably depending upon
the stage of lineage differentiation.
Based on a number of studies performed in the last
three decades, the regulation of self-renewal, com-
mitment, proliferation, maturation, and survival can
be assumed to reflect highly integrated processes
under control of extracellular mechanisms, including
regulatory molecules and microenvironment, as well
as intracellular mechanisms, including protoonco-
genes, cell cycle regulators, tumor suppressor genes,
transcription factors. Regulatory molecules include
positive (growth factors) and negative (interferons,
TGF-b, MIP-1a) factors which interact in complex
ways (synergism, recruitment, antagonism).13,14 Mol-
Figure 1. Possible patterns
of stem cell division. “S”
indicates a stem cell; “C”
indicates a committed prog-
enitor cell.
ecules that maintain the stem cell state are beginning
to be identified. These include ligands of the Notch
family receptors that act from outside the cell as reg-
ulators of proliferation or maintenance of the undif-
ferentiated state,15 and factors like PIE-1 that act
from within the cell.16 However, despite the efforts
which have been devoted to elucidating the issue of
self-renewal control, no factors have yet been identi-
fied that are capable of maintaining self-renewing
divisions and the molecular basis of self-renewal
capacity remains to be elucidated. Growth factors so
far identified more probably act as regulators of pro-
liferation and survival. Theoretically, growth factors
and cell-cell interactions can influence the outcome
of fate decisions by stem and progenitor cells in a
selective or instructive manner. According to selective
mechanisms, the stem cell commits to a particular lin-
eage independently of the growth factors and the fac-
tors act to control survival and proliferation of com-
mitted progenitors. In instructive mechanisms, growth
factors cause the stem cell to choose one lineage at
the expense of others. The relative contribution of
these two mechanisms to hematopoietic regulation
remains controversial, but experimental evidence sug-
gests that at least some subsets of stem/progenitor
cells can be instructed by growth factors to choose
one differentiation pathway at the expense of oth-
ers.17 In the absence of still unidentified instructive
signals, it can be hypothesized that environmental
signals may act by increasing or decreasing the prob-
ability of choosing a particular fate, rather than pro-
moting or repressing it in an all-or-none manner.2
Although growth factors play a key role in stem/pro-
genitor cell proliferation and differentiation it seems
improbable that hematopoiesis is regulated by a ran-
dom mix of growth factors and responsive cells.
Indeed, it is likely that regulatory molecules and local-
ization phenomena within marrow stroma are
required to sustain and regulate hematopoietic func-
tion.18 Stromal cells of the hematopoietic microenvi-
ronment provide the physical framework within which
hematopoiesis occurs. They play a role in directing the
processes by synthesizing, sequestering or presenting
growth-stimulatory and growth-inhibitory factors, and
also express a broad repertoire of adhesion molecules
which mediate specific interactions with hematopoi-
etic stem/progenitor cells.19 Differential expression of
adhesion molecules could cause different stem cell
subsets to home to different marrow microenviron-
ments capable of differently affecting self-renewal.
While much progress has been made in identifying
cytokines and stromal factors, little is known about
intracellular mechanisms  regulating hematopoietic
stem/progenitor cells self-renewal and differentia-
tion.20 Structure-function analysis of growth factor
receptors as well as identification of novel signal
transduction molecules have provided new insights
into the processes involved in signal transmission
pathways. Post-translational modifications of pre-
existing proteins, in particular tyrosine phosphoryla-
tion, play a key role in transmitting signals and there-
by linking extracellular signals to the activation of
nuclear effector molecules which govern gene expres-
sion.20 Accumulating evidence points to transcription
factors such as AML-1, Ikaros, SCL/Tal-1, Rbtn-2,
Tan-1, GATA-2, and HOX homeobox genes as
important regulators of these processes. Overexpres-
sion of HOXB4 in murine bone marrow cells marked-
ly increases the regenerative potential of long-term
repopulating cells and causes an expansion in clono-
genic progenitor cell numbers, without altering their
ability to differentiate normally into mature myeloid,
erythroid and lymphoid cells.21 In contrast, overex-
pression of HOXB3 causes defective lymphoid differ-
entiation and progressive myeloproliferation.22 The
glucocorticoid receptor, in combination with an acti-
vated receptor tyrosine kinase, seems to be a key reg-
ulator of erythroid self-renewal.23 Shc overexpression
increases GM-CSF sensitivity and prevents apoptosis
of the GM-CSF-dependent acute myeloid leukemia
cell line GF-D8, thus suggesting that Shc is an impor-
tant regulator of cell survival and proliferation.24 Dif-
ferent levels of protein kinase C modulate progenitor
cell phenotype by favoring myelomonocytic or eosi-
nophil differentiation.25 Recently, it has been shown
that telomerase expression correlates with hemato-
poietic self-renewal potential. Hematopoietic stem
cells show decreasing telomere length with increasing
age.26 Thus, telomerase may regulate self-renewal
capacity by reducing the rate of DNA  shortening.
Overall, intracellular mechanisms of hematopoietic
control result in the repression or de-repression of
lineage-specific genes regulating growth factor
responsiveness and/or proliferation potential.27 The
exact knowledge of these mechanisms will greatly
modify our approach to stem/progenitor cell manip-
ulation. 
In summary, stem and progenitor cell behavior is
the result of highly integrated phenomena based on
extracellular signals triggering intracellular transduc-
tion phenomena. The properties of self-renewal and
differentiation give stem cells their remarkable abili-
ty to repopulate the hematopoietic tissue of lethally
irradiated or genetically defective recipients. Under-
standing the interplay between extracellular and
intracellular regulatory factors in controlling lineage
determination remains an important challenge for
the future clinical use of hematopoietic cells. 
Stem cell antigen(s)
CD34 is a surface glycophosphoprotein expressed
on early lympho-hematopoietic stem and progenitor
cells, small-vessel endothelial cells, as well as embry-
onic fibroblasts.28 CD34+ hematopoietic cells are
morphologically and immunologically heterogeneous
and functionally characterized by the in vitro capabil-
ity to generate clonal aggregates derived from early
and late progenitors and the in vivo capacity to recon-
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stitute the myelo-lymphopoietic system in a myelo-
ablated host.29 The CD34+ cell population contains
virtually all the myeloid and lymphoid progenitors as
well as a small subset of cells that can initiate and
maintain stromal cell-supported long-term cultures.
Expression of the CD34 marker has dominated
attempts to isolate, purify and characterize human
hematopoietic stem cells by a variety of immunologic
means. 
Several monoclonal antibodies (MoAbs) assigned
to the CD34 cluster identify a transmembrane glyco-
protein antigen of 105-120 kd expressed on 0.5-2%
normal BM cells, 0.01-0.1% peripheral blood cells
and 0.1-0.4% cord blood cells.30 The function of the
CD34 antigen is not yet known, although it seems
that CD34 is involved in stem/progenitor cell local-
ization/adhesion in the marrow.31 CD34 antigen
expression is associated with the concomitant expres-
sion of several markers, including the lineage non-
specific markers Thy1, CD38, HLA-DR, CD45RA,
CD71 as well as T-lymphoid, B-lymphoid, myeloid
and megakaryocytic differentiation markers.30 Analy-
sis of the expression of CD38, Thy-1, CD71, the iso-
forms of CD45, and uptake of rhodamine-123 have
resulted in a consensus stem cell phenotype which is
CD34bright, Thy-1+, CD38–, CD45RA–, rh-123dull,
Hoechst 33342dull, Lin–. CD34+ cells also express
receptors for a number of growth factors classified as
tyrosine kinase receptors, such as the stem cell factor
receptor (SCF-R) or the stem cell tyrosine kinase
receptors (STK), and hematopoietic receptors, not
containing a tyrosine kinase domain.32 Tyrosine
kinase receptors are of particular relevance since their
ligands might represent new factors able to selectively
control stem cell self-renewal, proliferation and dif-
ferentiation.33 Recently, CD34– cells have been shown
to have functional characteristics associated with
stem cells and differentiate, in vivo, to CD34+ cells.34
Stem/progenitor assays to evaluate 
engraftment potential
Different types of progenitors can be measured
directly by multiparameter phenotyping of CD34+ cells
or subpopulations. Although this approach has the
significant advantage that the results may be quickly
available and can be used to guide clinical decisions,
correlations between progenitor cell phenotype and
functional activity are not yet refined enough to be
clinically applicable. In addition, although CD34 anti-
gen is expressed by virtually all progenitor cells, the
percentage of CD34+ cells with clonogenic activity in
vitro ranges from 10 to 50%. Non-clonogenic CD34+
cells include lymphoid progenitors as well as subsets
of cells which are unresponsive to conventional growth
factors and might require the presence of still
unknown factors able to activate stem cell specific
genes.14 Figure 2 shows a schema of the cellular orga-
nization of hematopoiesis based on in vitro and in vivo
functional properties of progenitor cells.
Recently, a new human hematopoietic cell, termed
the SCID repopulating cell (SRC), that is capable of
extensive proliferation and multilineage repopulation
of the bone marrow of nonobese diabetic
(NOD)/SCID mice has been identified.35,36 The SRCs
which are detected exclusively in the CD34+ CD38– cell
fraction have been shown to be biologically distinct
from CFC and most LTC-IC.35,36 With the exception of
transplantation of human cells into immunodeficient
mice, the identification of putative human stem cells
has essentially relied on in vitro assays. Short-term in
vitro assay systems require appropriate nutrients and
growth factors and are particularly suitable for mea-
suring quantitative changes of the different progeni-
tor cell types as well as for evaluating growth factor
responsiveness or investigating differential effects of
regulatory molecules on progenitors at different
stages of differentiation or on different hematopoiet-
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Figure 2. Cellular organization
of hematopoiesis.
ic pathways.37 Short-term assays are not suitable for
analyzing self-renewal or interactions of hematopoi-
etic progenitors with stromal cells. 
By using the long-term culture (LTC) technique, a
sustained production of myeloid cells can be readily
achieved in vitro, provided that a stromal layer is pre-
sent, when marrow (or blood) is placed in liquid cul-
ture at relatively high cell concentration, with appro-
priate supplements, temperature and feeding condi-
tions.37
The LTC system, based on the re-establishment in
vitro of the essential cell types and mechanism respon-
sible for the localized and sustained production of
hematopoietic cells in the marrow in vivo, offers an
approach able to investigate not only the proliferative
and differentiative events but also self-renewal of any
clonogenic cell types. A 5- to 8-week time period
between initiating cultures and assessing clonogenic
progenitor numbers allows a very primitive, self-
renewing human cell, the so-called long-term culture-ini-
tiating cell (LTC-IC) to be quantified.38,39 Limiting dilu-
tion assays allow the frequency of LTC-IC and their
proliferative potential (number of CFU-GM generat-
ed by each LTC-IC) to be calculated. Another assay
system, the cobblestone area-forming cell (CAFC),
uses a pre-formed stroma as a support for hemato-
poiesis.40 In this system, the primitive cells are mea-
sured directly by their ability to form characteristic
colonies of cells resembling cobblestones.
With the possibility of studying not only the differ-
entiation but also the self-renewal of primitive prog-
enitors, the LTC system will play an increasingly impor-
tant role in the design and assessment of new strate-
gies involving the genetic engineering of hematopoiet-
ic cells and marrow stromal cells. Hematopoietic cells
that can generate active hematopoiesis for weeks in vit-
ro or months in vivo after transplantation are considered
stem cells. This seems a clinically useful criteria,
because it characterizes those cells which are important
for sustained hematopoietic recovery following SCT.
However, it reflects an oversimplification of the rather
complex process of hematopoietic function. In fact,
the ability of a cell to provide long-term hematopoiet-
ic activity can either be due to a long period of quies-
cence after the initiation of the culture or be a function
of the probability of stem cell self-renewal which influ-
ences the long-term survival of stem cell clones.41 Thus,
the number of primitive cells measured in an LTC assay
will be the product of the number of stem cells present
at the onset of the culture and the probability of stem
cell self-renewal. Although LTC assays will likely predict
the in vivo repopulating activity of the graft, the clinical
definition of a stem cell does not consider those stem
cells that differentiate and die soon after transplanta-
tion or initiation of a culture.  
Preparation of hematopoietic cells for
ex vivo expansion
In the vast majority of cell culture systems, the pres-
ence of inhibitory mature and accessory cells limits the
degree of ex vivo expansion of the progenitor cell com-
partment. Thus, a higher production of total cells,
clonogenic cells and more immature hematopoietic
progenitors has been observed when purified progen-
itor cells (namely CD34+ cells) rather than the whole
BM, cord blood.42 or peripheral blood stem cell
(PBSC) collections43 are cultured ex vivo. Haylock et
al.43 selected and cultured 1,000 CD34+ cells in pres-
ence of a 10-fold excess of contaminating CD34–,
CD3–, CD14– cells and found no differences in total
cell production after 14 days of culture, as compared
to the production of 1,000 CD34+ cells grown alone.
However, when CD34+ cells were mixed with increas-
ing concentrations of  CD3+ CD14+ cells, a  marked
decrease in the total cell output was observed after
two weeks of culture suggesting an inhibitory activity
of monocytes and T-cells. Despite the lack of infor-
mation on CFU-C production, these results point out
that  the purity of the starting population is an impor-
tant variable and it was recommended that at least
50% of cells should be CD34+ in the initial cellular
input.43 There are also practical advantages in using a
purified stem cell population as starting material for
ex vivo manipulation, such as the ease of cell handling
and the amount of cytokines consumed in the culture.
Other variables that play an important role in stem
cell expansion, which will be discussed in detail in the
following paragraphs are:  initial cell density, different
cytokines used and their concentration,   the presence
of stromal cells, the composition of the culture medi-
um and the refeeding schedule. Conversely, it has been
recently demonstrated44 that CD34+ cells can be safe-
ly and efficiently processed after cryopreservation sug-
gesting that the availability of fresh hematopoietic cells
may not be an essential prerequisite for ex vivo expan-
sion. Moreover, whereas the majority of preclinical
and clinical studies45 have attempted to optimize the
expansion of highly enriched  CD34+ cells,  under cer-
tain circumstances it may be advisable to select earli-
er subfractions of progenitor cells such as CD34+ DR–
cells in chronic myelogenous leukemia (CML) or
CD34+ Thy-1+ lin– cells in multiple myeloma (MM). In
these diseases the CD34+ cell population is still cont-
aminated, to various degrees,  by malignant cells;46-49
therefore, isolation of primitive progenitors prior ex
vivo expansion may provide a starting cell population
with a high proliferative potential free of tumor cells.
Methods for hematopoietic progenitor cell (HPC)
enrichment
Several methods have been proposed for purifica-
tion of HPC (Table 1). Their final target is a cell pop-
ulation with optimal purity, viability and high prolif-
erative potential obtained by means of a low cost,
rapid and simple separation technique. Early attempts
toward the purification of HPC were based on the cell
physical properties. Density-gradient centrifugation,
velocity sedimentation and elutriation are methods
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that separate cells based on cell size and buoyant den-
sity. More recently, immunologic selection techniques
which take advantage of the expression of specific anti-
gens on HPC membrane, have allowed a much better
degree of enrichment. Specifically, the demonstration
of the presence of the CD34 antigen on HPC28 has led
to a number of positive selection systems which use
MoAbs to purify hematopoietic precursors. 
Alternatively, CD34+ cells can be enriched by deple-
tion of CD34– accessory and mature cells.
Fluorescence activated cell sorter (FACS)
Flow cytometry can be used to separate HPC from
a heterogeneous population after incubation of cells
with fluorochrome-conjugated MoAbs directed to
cell-surface markers. Moreover, multiparameter
enrichment can be obtained by combining physical
properties such as cell size and cytoplasmic granu-
larity and intracellular characteristics indicating cel-
lular function (e.g. propidium iodide to determine
cell viability; rhodamine-123 to assess metabolic qui-
escence and nucleic acid dyes to evaluate cycling sta-
tus). This cell sorting technique can yield a highly
purified (> 99%) cell population combining positive
and negative markers for HPC using clinically-graded
MoAbs. The main criticisms to the use of  flow
cytometry for selecting large numbers of cells are the
low recovery of target cells and the length of time
required to process the whole BM harvest or the
leukapheresis products. The development of multi-
parameter high-speed cell sorting has been described
and recently upgraded for clinical use.50,51 Viable cells
have been sorted at rates as high as 40,000 cells/sec
as compared to 2,000-5,000 cells/sec of commer-
cially available cell sorters. Thus, the sample pro-
cessing time can now be reduced to 8-12 hours. The
sorted cell fraction also maintains its hematopoietic
potential based on the presence of CFU-C, more
immature CAFC and long-term repopulating cells in
mice.51 Presently, selection of HPC (i.e. CD34+ Thy-1+
lin– cells) from clinical samples is directed toward the
purification of cell populations highly enriched for
HPC free of contaminating malignant cells in myelo-
ma patients.47
Panning
Anti-CD34 MoAbs  bound to the bottom of cell
culture flasks have been used to select CD34+ cells.52
The target cell population present in a heterogeneous
cell suspension is blocked on the plastic surface while
CD34– cells remain in the supernatant and can be
easily eliminated. 
Despite the good results reported, the availability
of more efficient methods of cell separation have
made this technique largely redundant. 
Immunomagnetic systems
A variety of magnetic cell-separation methods have
been described.53 Some of these systems are com-
mercially available and have been used in clinical tri-
als. The main differences between the currently used
magnetic cell-separation methods are the composi-
tion and size of the magnetic particles used for label-
ing the cells and the separation process. Superpara-
magnetic beads can be equally used for negative and
positive cell separation depending on the specificity
of MoAbs. The rosetted target cells can be easily iso-
lated from unlabeled cells by a magnet applied on
the outer wall of the test tube or blood bag. Large
magnetic beads (diameter >0.5 µm) have been used
clinically for the purging of neuroblastoma and lym-
phoma cells from stem cell harvests prior to autolo-
gous transplantation.53,54 Immunomagnetic beads
coupled with anti-CD34 MoAb can be used for pos-
itive selection of HPC.55 However, before the clinical
use of the enriched cell fraction, the cell-bound par-
ticles must be removed to avoid damage to the cells
and/or toxic events to the patient. Beads can be
released using chymopapain or a peptide competing
with the CD34 Ab. In alternative, HPC can be
enriched by negative depletion of mature and acces-
sory cells targeting lineage-specific antigens.
More recently, the magnetic cell-sorting (MACS)
system has been proposed as an efficient and more
manageable alternative to flow cytometry for cell sep-
aration.56 It uses colloidal-sized superparamagnetic
particles made of dextran and iron oxide with 60 nm
of diameter. The use of very small beads minimizes
unspecific binding and allows the efficient isolation
of rare cells. In addition, the magnetic particles are
readily internalized by the labeled cells without affect-
ing their physical, phenotypic and functional capac-
ity.57 Table 2 reports the results of a large number of
experiments (=14) comparing the efficiency of the
Mini-MACS system for selecting CD34+ cells from
two different cellular sources (R.M.L., unpublished
observations).  
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Table 1. Hematopoietic cell separation systems.
Recovery Purity Clinical grade
(% of initial cells)(% CD34+ cells) device 
Immunomagnetic beads
Negative selection 20-50 20-60 Yes
Positive selection 30-60 50-90 Yes
MACS >80 >90 Under 
evaluation
Panning 30-50 40-70 No
Avidin-biotin 40-60 50-90 Yes
immunoabsorption
FACS (high-speed 30-50 >95 Yes
cell sorting)
High-affinity chromatography based on avidin-
biotin immunoabsorption
This technique relies on the high affinity between
the protein avidin and the vitamin biotin whose inter-
action has an extremely high dissociation constant (=
10-15 M). In this system, a heterogeneous cell popu-
lation is incubated with a biotinylated antibody to
the CD34 antigen. The cell mixture is then passed
through a disposable column containing avidin-coat-
ed polyacrylamide beads. CD34+ cells are retained on
the column due to the high affinity binding of biotin
to avidin while negative cells are washed away. Target
cells are then recovered by mechanical agitation of
the column which disrupts the antibody-antigen link.
Thus, bound cells are eluted from the column main-
ly free of antibody. An automated version of the
device controlled by a computer which guarantees
reproducibility and reduces risks of operator errors
has been developed and used in the setting of autol-
ogous and allogeneic stem cell transplantation.46, 58
Dynamic systems 
In addition to positive or negative selection of
CD34+ cells, effective ex vivo expansion of hema-
topoietic progenitor cells and, perhaps, putative stem
cells can also be achieved in the presence of unse-
lected cell populations. In this case the use of dynam-
ic perfusion cultures is strictly required. As stated
above, the production of inhibitory factor(s) by
mature and accessory cells rather than the availabil-
ity of growth promoting factors, is probably the main
limitation to successful stem cell expansion. For
instance, it is well known that suboptimal cell expan-
sion occurs when CD34+ cells are cultured at con-
centrations exceeding 104 cells/mL. Moreover, the
presence of stromal feeder-layer cells seems to be
important for effective BM stem cell expansion
induced by exogenous cytokines. Therefore, an arti-
ficial capillary-perfusion system (Bioreactor) in which
nutrients consumed by proliferating cells are contin-
uously replenished by exchange of the nutrient-
depleted medium with fresh culture medium, has
been tested for ex vivo expansion of hematopoietic
cells co-cultivated with stroma cells or stromal cell
lines.59 Cytokines such as IL-3, IL-6 and GM-CSF have
been added to the culture to optimize cell expansion
and to provide growth factors which are not pro-
duced by stromal cells (i.e. IL-3). In this system, cul-
tured cells are confined in a small compartment sep-
arated from a large medium reservoire. Medium
exchange is optimized when there is a maximal mem-
brane surface area per unit volume across which
medium and nutrients can pass by diffusion. This is
best achieved by a capillary-perfusion module. Three
important requirements for optimal expansion of
hematopoietic cells are: the capillary porous size, the
capacity of supporting the attachment of stromal
cells by the module and the minimal cell activation by
the materials of the module. In fact, mature myeloid
cells such as macrophages release ,upon surface acti-
vation, tumor necrosis factor(s) (TNFs), interferon(s)
(IFNs) and other substances which negatively affect
stem cell expansion. 
Bioreactors have induced a remarkable expansion
of committed hematopoietic progenitor cells cou-
pled with a modest increase in the number of LTC-
IC,59 a population of primitive cells which correlates
most positively with the long-term reconstituting
capacity of autologous and allogeneic grafts.
Ex vivo expansion of myeloid progenitor
cells
Ex vivo expansion of hemopoietic progenitors might
result in:
• amplification of the population of committed pro-
genitors due to an extensive, although controlled,
differentiation process;
• amplification of the stem cell pool through exten-
sive self-renewal of the early progenitor cell popu-
lation.
Obviously, both processes can take place simulta-
neously mimicking, in vitro, the complex interplay of
regulatory mechanisms that allows hemopoiesis in
vivo. The latter situation, so far, has never been
obtained in vitro, whereas different approaches have
permitted  the first goal to be reached (at least, to a
certain extent) and some recent data suggest that rel-
evant self-maintaining processes can be triggered.
The clinical relevance of extended differentiation
versus self-renewal is obviously different. The induc-
tion of an increased in vitro production of committed
progenitors might hasten the early phases of hemo-
poietic reconstitution which occur after myeloabla-
tive treatment and stem cell transplantation. More-
over an increased number of infused cells might mod-
ulate graft versus-host disease (GVHD) intensity in
the allogeneic setting.60
Although relevant, the potential clinical benefit of
techniques allowing only committed progenitor cell
expansion is outweighed by the possibility of trigger-
ing the self maintenance, and perhaps amplification,
of early hemopoietic progenitors. In this situation,
starting from a limited number of progenitors, long-
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Table 2. High efficiency of Mini-MACS separation system for
the enrichment of BM or circulating CD34+ cells.
Enrichment
Source Pre Post Recovery CE* LTC-IC
(%) (%) (%) (x104 CD34+)
BM 2.3±1 97±3 88±9 3.6±0.3 62.5±54
PB 0.7±0.4 98.9±1 90±8 3.9±0.4 48.2±35
*Abbreviations: CE, clonogenic efficiency; BM, bone marrow; PB, peripheral
blood. The results are expressed as mean±SD.
 
term reconstitution of hematopoiesis might become
feasible. Moreover, ex vivo manipulation of primitive
hemopoietic cells could be performed under experi-
mental conditions suboptimal for the growth of neo-
plastic cell contaminating autologous grafts. Thus,  a
purging effect could be obtained.
Several attempts of in vitro expansion of hemopoi-
etic progenitors have been published in the last years.
Recent reviews61, 62 summarize early experiences.
The first studies on ex vivo generation of hematopoi-
etic progenitors involved liquid culture in the pres-
ence of cytokines such as SCF, IL-1, IL-3, IL-6, G-CSF,
GM-CSF  and Epo. These experiences showed that a
relevant increase (from 10 to 1,000 fold) of CD34+
cells and of committed progenitors can be  obtained.
The expansion of committed progenitors does not
mean, however, that the long-term reconstitution of
hemopoiesis is achievable. Indeed, several data sup-
port the concept that an uncontrolled commitment
decreases the stem cell pool. Yonemura et al.63 have
reported that IL-3 or IL-1 abrogates the reconstitut-
ing ability of hematopoietic stem cells. Furthermore,
Peters et al.64 have demonstrated that ex vivo expan-
sion of murine marrow cells with IL-3, IL-6, IL-11 and
SCF leads to impaired engraftment in irradiated
hosts. 
As indicated by Traycoff et al.65 ex vivo expansion of
hematopoietic cells using SCF, IL-1a, IL-3 and IL-6
generates classes of cells possessing different levels
of BM repopulating potential based on their cycling
status. Along this line, Young et al.66 correlated a high-
er proliferative capacity with a quiescent status after
ex vivo expansion in the presence of SCF, IL-3, IL-6
and LIF.  Taken together, these data suggest that cul-
tures in the presence of cytokine combinations based
upon SCF, IL-1 and IL-3 involve differentiation of BM
or mobilized CD34+ cells entering the S phase. Dif-
ferent results were obtained by Di Giusto et al.,67 who
found that ex vivo expanded cord blood CD34+ cells
repopulated the marrow of immunodeficient mice as
well as non-expanded cells. However, it must be
remembered that cord blood is rich in hemopoietic
progenitors68 that have an increased proliferation
potential.69
New strategies to induce the expansion of CD34+
cells  with little (or no) differentiation might involve
different approaches. The use of stirred suspension70
or hollow fiber71 bioreactors has been proposed in
order to grow cells in a more physiologic environ-
ment, and inhibitors such as TGF-b and MIP-1a have
been the object of  intense studies. Recently, MIP-1a
has been found to exert a weak inhibitory effect on
CD34+CD38– cells and to enhance the proliferation
of CD34+CD38+ cells, whereas TGF-b strongly
inhibits both cell populations.72,73 The most promis-
ing results, however, have been obtained with the
recent introduction of FL and Tpo. FL, a recently dis-
covered member of the class III tyrosine kinase recep-
tor family,74 is able to induce proliferation of very ear-
ly hematopoietic progenitors that  are nonresponsive
to other early acting cytokines, and to improve the
maintainance of progenitors in vitro.75-77 This is also
supported by the finding that FL significantly reduced
the number of cultured cells undergoing apoptosis.78
Analysis of the effects of 16 cytokines on CD34+
CD38– cells showed that FL, SCF and IL-3 produced
a 30-fold amplification of the input of LTC-IC.79
Yonemura et al.80 compared FL- and SCF-driven ex vivo
expansion. They reported that both cytokines, in
combination with IL-11, enhanced the production of
progenitors, but with different kinetics. In fact, the
maximal expansion by FL required a longer incuba-
tion than with SCF. Interestingly, in these studies the
combination of SCF/IL-11, together with IL-3,
reduced the ability of cultured cells to reconstitute
hematopoiesis in irradiated hosts.80 Other recent
data have compared the effect of FL and SCF. FL acts
as a self-renewal or proliferation/expansion signal for
CD34+-low cells while the effect of SCF is more like-
ly to transduce a differentiation signal, resulting in
more rapid repopulation at the expense of cell expan-
sion.81 Gene transfer studies in mice have also
demonstrated that FL maintains the ability of human
CD34+ cells to sustain long-term hematopoiesis. In
fact, incubation of CD34+ cells with FL before trans-
duction was associated with long-term provirus
expression, whereas provirus expression declined in
recipients of CD34+ cells transduced in the absence
of FL.82 The expansion ex vivo of early progenitors
seems to be affected at the single cell level by changes
in cytokine concentrations. In a recent paper by the
Vancouver group,83 maximal LTC-IC expansion was
obtained in the presence of 30 times more FL, SCF,
IL-3, IL-6 and G-CSF than could concomitantly stim-
ulate the near-maximal amplification of CFC.
Tpo, the ligand of the mpl receptor expressed on
both early and committed hematopoietic progeni-
tors,84 is known to support megakaryocytopoiesis.85
Moreover, it has been shown to be capable of enhanc-
ing  ex vivo expansion of early/committed progenitor
cells. As single factors, FL and Tpo stimulated a net
increase of LTC-IC generated from CD34+ CD38– cells
within 10 days.79 Furthermore, as demonstrated in
mice recipients of  BM cells transduced with the mpl
receptor,86 Tpo does not induce lineage-restricted
commitment of mpl-receptor positive pluripotent
progenitors but permits their complete erythroid and
megakaryocytic differentiation. Tpo has also been
found to increase the multilineage growth of CD34+
CD38– cells from 3%, in absence of the cytokine, up
to 40% when Tpo is added to SCF and FL.87 The pres-
ence of additional cytokines such as IL-3, IL-6 and
Epo does not significantly enhance clonal growth
above that observed in response to Tpo, SCF and FL.87
lnterestingly, the soluble form of Tpo receptor and G-
CSF receptor directly stimulate the proliferation of
primitive hematopoietic progenitors of mice in syner-
gy with SCF and FL.88
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A step toward extensive ex vivo amplification of ear-
ly human progenitor cells has been reported by Piaci-
bello et al.89 They first demonstrated that IL-3 induces
an early production of committed progenitors but is
not able to sustain true self maintenance of hemo-
poietic stem cells even in the presence of other early
acting cytokines (FL, Tpo, SCF). Afterwards, several
combinations of early acting cytokines were tested
for their ability to sustain long-term hematopoiesis in
stroma free cultures. Among the various combina-
tions tested on purified cord blood CD34+ cells, the
mixture of Tpo + FL was found to be able to maintain
early progenitors up to six months.89 These data indi-
cate the enormous potential of cord blood progeni-
tors and the key role of Tpo and FL in the regulation
of early hematopoiesis. However, several issues
remain to be clarified:
• is it true self-renewal or a slow differentiation of
cord blood cells, which are rich in immature  prog-
enitors?
• what is the in vivo repopulating capacity of ex vivo
expanded cells?
• is such expansion possible using CD34+ cells
obtained from the marrow or peripheral blood of
adult subjects?
In this view, while a number of papers have already
reported that committed progenitors can be gener-
ated and safely administered to transplant recipients,
there are no reports on expansion of cells with long-
term repopulating capacity in humans.  
Brugger et al.45 reported  the successful reconstitu-
tion of hematopoiesis in ten cancer patients trans-
planted with autologous cells generated from CD34+
cells cultured in the presence of SCF,  IL-1b, IL-3, IL-
6 and Epo. However, the conditioning regimen given
to these patients was not fully myeloablative, and this
study offered no insight into the long-term engraft-
ment potential of cells generated in this fashion. A
similar approach was followed by Alcorn et al.44 In
ten patients with malignancy, an aliquot of the PBSC
harvest was recovered from liquid nitrogen and CD34
were selected. Cells were cultured for 8 days in the
presence of the same cytokine combination. A mean
of 3793106 expanded cells were reinfused in addition
to unmanipulated cells. The authors reported that
the total LTC-IC number was not increased and most
of the CD34+ cells were differentiated in front of an
average 15-fold CFU-GM expansion (range 4-39).
Similarly, averages of 71 (range 27-151)-fold mega-
karyocytic cell expansion and 1,040 (19-16.000)-fold
erythroid cell expansion were reported. Although
adverse reactions were not reported,  no difference in
the kinetics of engraftment was observed in compar-
ison with historical controls.
Different results come from preclinical studies
where the infusion of large numbers of ex vivo expand-
ed committed hematopoietic progenitors, together
with unmanipulated cells might speed engraftment
after chemotherapy and/or total body irradiation
(TBI). Data from Uchida et al.90 have suggested in the
past that most of the short- as well as the long-term
engraftment potential resides in uncommitted prog-
enitors. More recently, Szilvassy et al.91 have demon-
strated that partially differentiated ex vivo expanded
cells accelerate hematologic recovery in myeloablat-
ed mice transplanted with highly enriched long-term
repopulating stem cells. In humans, Williams et al.92
reinfused 9 breast cancer patients with unmanipu-
lated apheresis products together with a mean of
443106/kg  mature CD15+ cells generated ex vivo by
CD34+ cells cultured in the presence of PIXY-321. No
toxicity was observed after reinfusion, and time of
white cell recovery was similar to that observed in the
retrospective control group. In a more recent study,78
megakaryocytic progenitors (MP) were obtained
from CD34+ cells cultured in serum-free medium in
the presence of Tpo, FL, SCF, IL-3, -6, -11 and MIP-
1a. Proliferation peaked on day 7 in culture, and a
8±5-fold expansion of CD34+/CD61+ cells, a 17±5-
fold expansion of CFU-MK and a 58±14-fold expan-
sion of the total number of CD61+ cells was obtained.
Ten cancer patients undergoing autologous PBPC
transplant received MP generated ex vivo (range 1-21
CD61+ cells 3105/kg) together with unmanipulated
PBSC. Platelet transfusion support was not needed in
2 out of the 4 patients receiving the highest dose of
cultured MP  and this result compared favorably with
a retrospective control group of 14 patients, all
requiring platelet transfusion support. A major con-
cern is the potential expansion of contaminating
tumor cells along with hematopoietic progenitors. In
fact, it has been demonstrated that CD34+ cell selec-
tion decreases (but does not abrogate) neoplastic
cell contamination from aphereses of myeloma
patients.46 For instance, in the majority of B cell lym-
phoma patients CD34+ cell selection does not elimi-
nate contaminating t(14;18)+ cells. However, during
ex vivo expansion residual lymphoma cells do not pro-
liferate and become undetectable by molecular analy-
sis in the majority of cases.93 Similarly, Vogel et al.
recently indicated that exogenously mixed epithelial
tumor cell lines might have a relative disadvantage
over CD34+ cells during ex vivo expansion.94
Future directions
Future challenges in this field are represented by
the expansion of true human stem cells without mat-
uration, to extend this strategy to allogeneic stem cell
transplantation, and especially cord blood allograft,
as well as  the manipulation of cycling of primitive
progenitors for gene therapy programs.
Selective amplification of specific myeloid lineages
(e.g. platelets or granulocytes) may improve the results
of autologous transplantation. Moreover, although
early results need confirmation, the amplification of
early/committed hematopoietic cells coupled with the
removal of neoplastic cells contaminating autologous
grafts appears to be feasible. 
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Expansion of cytotoxic effectors
Human cytotoxic effector (CE) cells can be divid-
ed in two major groups:
1. cells requiring prior antigen sensitization, which
recognize their target in the context of the major
histocompatibility complex (MHC) molecules;
2. cells not requiring prior antigen sensitization being
spontaneously cytotoxic against tumor target cells
(e.g. K-562 cell line) in a non-MHC restricted set-
ting.
While the first group includes only some subsets
of T-lymphocytes (CD8+ or CD4+ cells), the second
one is more heterogeneous and includes both T-cells
and natural killer (NK) cells, expressing the CD56
antigen.95
The so-called antibody-dependent cellular cyto-
toxicity (ADCC) can be mediated by cells expressing
the Fcg receptor II and the Fcg receptor III (e.g. NK
cells and CD3+/CD16+ cells). Although this activity is
not exhibited by non MHC-restricted cells, it cannot
be considered aspecific and it is also exerted by mo-
nocytes.
The lymphokine-activated killer cells (LAK) are
capable of killing NK-resistant cellular targets (e.g.
Daudi cell line). Although some tissue-resident lym-
phocytes may have spontaneous LAK activity, nor-
mal blood mononuclear cells do not show any LAK
activity, which can be acquired after incubation with
Interleukin-2 (IL-2).96
Therefore the LAK assay is a measure of the capac-
ity of T and NK cells to become activated and to
express cytolytic function.
Killing mechanisms of cytolytic effectors
Cytotoxic T-Lymphocytes (CTL) and NK cells pos-
sess at least two distinct, fast-acting, lytic mecha-
nisms:97, 98
1. the granule exocytosis pathway involves the secre-
tion of perforin and granzymes which penetrate
throughout the target cell pores, inducing cell
death;
2. a non-secretory mechanism which is mediated by
the interaction between the Fas-ligand, expressed
by the killer-cell and Fas (CD95) which triggers a
cascade of proteolytic enzymes leading to apop-
tosis of both the killer and the target cell.
A third cytolytic pathway, involving TNF, has
recently been described.99
A series of apoptosis-resistant clones of human
lymphoma cells has been described. These cells
express fas/APO-1 receptors lacking the intracyto-
plasmic signaling domain.100
NK cells, as well as CTL, can recognize MHC class
I molecules. However, recognition of MHC on target
cells downregulates the NK cell function, suggesting
the presence of inhibitory receptors.101
LAK cells are not MHC-restricted and are also
capable of killing freshly isolated tumor cells. Simi-
larly to CTL and NK cells, their activity is mediated by
both lytic pathways (perforin/granzyme) and Fas-
mediated apoptosis.
Cytokines involved in CE function
Several cytokines affect CTL and NK cell response.
In particular, IL-2 expands the pool of alloreactive
CTL precursors and IL-15 (produced by monocytes)
mimics IL-2 action by inducing g-IFN production, the
activation of memory T cells and CTL proliferation.102
In addition, GM-CSF can affect certain T-lympho-
cyte functions by enhancing their cytotoxicity and g-
IFN production. This multifunctional cytokine can
also augment NK cell function and the expression of
adhesion molecules on the surface of leukemic
cells.103,104 Moreover, it has been hypothesized that
the association of GM-CSF/IL-2 can also be useful for
the activation of cytotoxic effectors by circulating
progenitors, preserving the clonogenic potential of
normal hemopoietic precursors.105
IL-12 elicits the production of g-IFN by CTL thus
enhancing their antineoplastic efficacy and promotes
the differentiation of T-helper-1.106,107 Finally, IL-7
seems to be critical for the development of CTL and
for a fast immune reconstitution after bone marrow
transplantation (BMT).108
In conclusion, these cytokines play a pivotal role in
the immune response against tumor cells by expand-
ing,  activating and recruiting CE and secondary effec-
tor cells (macrophages) or by directly inhibiting
tumor cell growth.
Role of cytotoxic effectors in immunosurveillance
There are several in vitro and in vivo data supporting
the role of  immunosurveillance in tumor growth con-
trol.109 The graft-versus-leukemia (GVL) effect has
been demonstrated to play a critical role in the erad-
ication of minimal residual disease (MRD) after allo-
geneic trasplantation and there is evidence support-
ing the role of both T cells and NK cells in preventing
disease relapse.110
Today, there is no doubt that CTL have a major
role in killing allogeneic tumor cells in a MHC-restrict-
ed manner. For example, in CML, the higher relapse
incidence after T-cell depleted allogeneic BMT111 and
the dramatic effect of donor T-lymphocyte infusion
after relapse following BMT,112 strongly support the
importance of MHC-restricted GVL.
Unfortunately, a selective GVL effect (separated
from GVHD) can be obtained very rarely in patients
receiving allogeneic BMT. Moreover, although ani-
mal models indicate that autologous GVHD exists
and could generate a significant antitumor effect, the
high incidence of relapse in patients receiving autol-
ogous BMT demonstrates that  autologous GVL is
often clinically ineffective.113
Rationale for cytotoxic effectors’ expansion
There are many important reasons to increase the
number, the efficacy and the specificity of cytolytic
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effectors both in the allogeneic and in the autolo-
gous setting.  The main clinical goals are the follow-
ing:
1. to reduce the relapse-incidence after autologous
BMT, which is still relevant in acute leukemia, lym-
phoma and breast cancer;
2. to cure diseases in which autologous BMT can
only prolong the survival (multiple myeloma,
CML, metastatic chemosensitive cancers);
3. to reduce the incidence of relapse after allogene-
ic BMT  especially in patients transplanted with
great tumor burden;
4. to accelerate the immune reconstitution after
BMT, in order to reduce the morbidity and trans-
plant-related-mortality caused by serious infec-
tions (e.g. CMV and systemic mycosis).
The CE which are investigated for in vivo or ex vivo
expansion are mainly NK cells in the autologous set-
ting and CTL in the allogeneic setting.
Development and expansion of NK cells 
NK cells belong to the naive part of the immune
system and begin to appear into PB early after allo
and auto-BMT. These cells express the N-CAM
homologous CD56 antigen, but lack T-cell receptor
a/b complexes. They are also characterized by low
affinity receptors for IgG (CD16)114-116 and their bind-
ing to malignant cells is mediated by CD18 mole-
cule.117 The most important organ for NK differenti-
ation is the BM. Several data suggest that a common
precursor of T cells and NK cells does exist. Fetal NK
cells express the TCR g, d, e, j sub-units while fetal B
precursors do not express TCR subunits (Figure 3).
These bipotential T/NK precursors do not have
TCR rearrangement and share CD34/CD33/CD7
antigens. They differentiate to NK in the presence of
SCF, IL-7, IL-2 and stromal feeder cells. The first step
of NK differentiation is stroma-dependent while the
second step of NK maturation is stroma-independent
and is strongly potentiated by the association of IL-
2 with IL-7.118 In all studies IL-2 is required for NK cell
differentiation from CD34+ cells. This finding sug-
gests that a fraction of CD34+ cells expresses IL-2
receptors and that activated T-cells (as IL-2 source)
should be detectable in the cellular milieu. However,
T-cell deficient mice have normal NK cell develop-
ment and  humans lacking the g-chain subunit of IL-
2R lack NK activity. These unexpected observations
have recently been supported by the demonstration
that IL-15, produced by BM stromal cells, can direct-
ly induce CD34+ cells to differentiate into CD3–/56+
NK cells in the absence of IL-2.119
The last step of NK development, after the expres-
sion of CD16, is characterized by the appearance of
the CD56 molecule. The intensity of CD56 expres-
sion directly correlates with the proliferative potential
and the killing ability of  NK cells.120
There is clear evidence that mature NK elements
have a clonally-distributed ability to recognize their
target cell by class I MHC alleles and a precise corre-
lation has been established between the expression of
p58 receptors on NK cell surface and class I MHC
alleles. These receptors transduce an inhibitory signal
upon interaction with MHC class I antigens, to pre-
vent NK cells from killing  target cells expressing cer-
tain (self) HLA alleles.
These findings are consistent with a self-tolerance
mechanism exerted by the NK population which can
be disrupted as a consequence of tumor transfor-
mation or viral infection or any other events inducing
(or masking)  class I molecules.121,122
After incubation with IL-2, NK cells become LAK
cells capable of killing otherwise NK-resistant target
cells. These (NK) activated cells express new markers
such as CD25, MHC class II and fibronectin which
can be useful for the evaluation of their functional
state. The NK cell compartment is heterogeneous and
distinct subsets have been characterized. The most
informative functional differences are based on rela-
tive CD56 fluorescence: only CD56+bright, but not
CD56+dim NK cells, express the high-affinity IL-2 recep-
tor. As a consequence, they respond to low  concen-
trations of IL-2 and expand 10 times more than
CD56+dim. This subset seems to be significantly
reduced in leukemic patients. A remarkable reduc-
tion of CD56+bright NK cells has been observed in CML
patients coupled with a significant decrease of their
spontaneous cytotoxicity against the K-562 line.
However, this defect was corrected by 18 hours incu-
Figure 3. NK cells differentiation pathway. 
Modified from Miller et al, Blood 1994; 83: 2594-601.
 
bation with 1000 U/mL of recombinant IL-2.120 These
data strongly suggest that during tumor progression,
the NK compartment (and particularly the small frac-
tion of NK-CD56+bright with high proliferative ability)
is progressively suppressed even though the exoge-
nous administration of IL-2 can partially reverse this
phenomenon. The strong correlation between func-
tional capacity of the NK cell compartment and
tumor progression has often been reported as well as
the efficacy of the administration of LAK cells plus IL-
2 in restoring an anti-tumor response.123
Along this line, more than 90% of patients with
acute leukemia in complete remission do not show
spontaneous cytotoxicity against autologous blast
cells. However, ex vivo treatment with IL-2 restores
cytolytic activity in 37.5% of these patients.124
The first attempts to generate and expand LAK
activity either in vivo or in vitro (after ex vivo incubation
with IL-2) have been clinically disappointing espe-
cially in patients autotransplanted for acute lym-
phoblastic leukemia (ALL).125 Nevertheless, there is
now a renewed interest in the use of activated NK
cells in hematologic malignancies, based on the opti-
mization of different approaches: 
• administration of IL-2 in vivo to expand function-
ally active CE in patients with low tumor-burden,
in order to reach an optimal effector/target ratio;
• harvesting and culturing large amount of NK cells
for additional ex vivo expansion/activation with IL-
2. Expanded cells should be reinfused in the early
phase after BMT;
• sequential combination of both techniques  (Fig-
ure 4).126
The systemic administration of IL-2 for in vivo
expansion and activation of the NK compartment
may theoretically have some  advantages:
1. high number of CE precursors in the body;
2. possibility of activating CE residing in the tumor
bulk;
3. more feasible  and cheaper strategy than the gen-
eration and administration of LAK cells.
On the other hand, the main drawbacks of this
approach are the high toxicity of systemic adminis-
tration of IL-2 and the high variability of anti-tumor
response.
Sources of cytotoxic effectors and modalities
of NK cell expansion
Human NK progenitor cells can normally be found
in the BM,127,128 and originate from CD34+ hemato-
poietic progenitors.129 So far,  the generation of NK
cells from CD34+ precursors has been described  on a
small scale basis  but not in large scale experiments.130
High numbers of functionally active NK cells can be
easily demonstrated in mobilized cells from patients
receiving chemotherapy plus G-CSF. Silva et al.131 have
shown a 5.4-fold expansion of NK cells from leuka-
pheresis products incubated in the presence of IL-2
for 6-8 days without affecting the CD34+ cell con-
tent. However, decreased function of NK cells has
recently been described in the PB of normal donors
after G-CSF administration.132 Circulating NK prog-
enitors showed a decreased killing capacity and
diminished proliferative ability in response to IL-2, as
compared to their unprimed BM counterpart.
Based on previously published LAK trials,123, 133 it
can be estimated that about 1010-1011 activated NK
cells are needed to stimulate an anti-tumor response.
A 100-fold ex vivo expansion of these cells from a  stan-
dard leukapheresis collection would, therefore be
required to obtain such a high number of effectors.
Beaujean et al.134 reinfused autologous BM  cells
incubated for 10 days  with IL-2 in 5 ALL patients fol-
lowing a myeloablative treatment. This procedure
resulted in an important loss of hemopoietic prog-
enitors with delayed engraftment. Moreover, in spite
of this attempt to induce an autologous GVL, all
patients eventually relapsed.134
Wong et al.135 compared the ability of IL-2 alone or
combined with IL-7 or IL-12 to stimulate NK activity
in BM or  PB samples. They found that IL-2/IL-12-
activated blood cells suppressed the growth of the
leukemia cell line K-562 about eight-fold more effi-
ciently than BM cells. They also found that cryo-
preservation and subsequent stimulation of BM and
PB cells did not significantly decrease the activity of NK
cells.  Finally, the combination of IL-2 and IL-12
showed a synergistic effect on both BM and  PB ele-
ments.135 Large-scale ex vivo expansion of NK cells for
adoptive immunotherapy not only requires an opti-
mal source of precursors, but also clinically approved
materials and procedures. In this context, Miller et
al.136 obtained a 21-fold expansion of NK cells using
a 21-day large scale NK culture performed in gas-per-
meable bags. Pierson et al.137 observed a 352-fold
expansion of NK cells after 33 days of incubation in
a bioreactor. Their starting population was NK pre-
cursors enriched by negative panning with anti-CD5
and anti-CD8 antibodies. The activated NK popula-
tion  was highly purified (>90%) in CD56+ /CD3– cells
and maintained a powerful cytotoxicity against K-
562 cells.
The use of a homogeneous NK cell fraction for cell-
therapy programs seems to be advantageous because
activated NK cells have more specific lytic activity
than heterogeneous LAK populations.138 However,
creating such a fraction requires a first step of enrich-
ment (e.g. by eliminating CD8+/CD5+ cells) and long-
term cultures carry the risk of fungal or bacterial con-
tamination.
Cytokine induced killer cells (CIK) expansion
In 1986 Lanier described a subset of CD3+ T cells
co-expressing the CD56 antigen which is a typical NK
marker.139 A remarkable expansion of this cellular
subset has recently been obtained by Schmidt et al.140
following a 16-day incubation in the presence of
IFNg, IL-1, IL-2 and a monoclonal antibody against
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CD3 as the mitogenic stimulus. The ability of CIK
cells to deplete  leukemic cells from CML marrow was
then investigated by the same group.141 While stan-
dard LAK cells were, in most cases, unable to lyse
CML cells, CIK cells were toxic to both autologous
and allogeneic CML blasts without affecting normal
hemopoietic progenitors.
CTL expansion for adoptive therapy
It is well known that the GVL effect can be trans-
ferred with donor-buffy-coat (BC) lymphocytes.142
The antitumor effect of the CTL contained in the BC
has been shown to be more potent than that induced
by NK cells, even though NK cells exert a GVL activi-
ty different from GVHD.143
In a murine model, a single dose of 23107 CTLs in
tumor bearing mice (DBA/2) resulted in the eradica-
tion of primary cancer and metastases without caus-
ing severe GVHD.144 Unfortunately, this GVL effect
cannot be easily separated from GVHD in humans.
As a matter of fact, in clinical studies the beneficial
effect of CTL administration is often offset by the
severity of GVHD or marrow aplasia.
Although leukemic cells share common antigens
with other tissues of the host, there is also the chance
that distinct leukemic antigens may be recognized by
specific allogeneic CTL.145
Leukemia-specific T-cell clones have been isolated
from HLA-identical siblings146 and this finding may
explain the high incidence of CR, without GVHD, in
patients with CML relapsed after allo-BMT and treat-
ed with donor BC.147
The subset of donor-lymphocytes involved in the
GVL effect is not entirely defined. Both CD4+ and
CD8+ GVL effectors have been described in animal
models. Recent studies in man suggest a prominent
role of CD8+ cells in acute leukemia and CD4+ cells
in CML.148 The therapeutic index of this approach
may be increased  by treating the donor lymphocytes,
previously activated with recipient PHA-stimulated
blast, with anti-CD25 ricin-conjugated antibodies.149
This procedure gives origin to a CTL population
which retains over 75% of its antileukemic activity
with only 10% of the initial responsiveness against
the non-leukemic cells of the recipient.
Strategies for generation and expansion of
specific CTL
A very attractive system for generating and expand-
ing CTL is based on the selection and isolation of
tumor-specific peptides (e.g. those encoded by bcr-
abl or PML-RARa fusion genes) and to presenting
them to T-cells to stimulate a specific T-cell response.
The responding T-clones can then be amplified and
selected by limiting dilution techniques. Unfortu-
nately, in many cases the tumor-specific peptide is
not presented by leukemic cells making the generation
of peptide-specific CTL useless.150 In this regard, the
Figure 4. Strategies for generation and activation of NK cells in vitro and in vivo. Modified from Klingemann et al., Exp Hema-
tol 1993; 21:1263-70.
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transfection in tumor cells of DNA sequences encod-
ing for co-stimulatory molecules (B7-1) or cytokines
such as GM-CSF has greatly enhanced the anti-tumor
response of T-cells. Alternatively, the use of profes-
sional antigen presenting cells (APC), primed with
tumor specific antigens (e.g. tumor specific idiotype
in low-grade B-cell lymphoma) has proved to be effec-
tive for the generation of tumor-specific CTL clones in
vivo capable of inducing  a measurable anti-tumor
response.151 Allo-CTL have also been used against
EBV-related lymphoma developed in allograft recipi-
ents and HIV patients. EBV infection is controlled in
normal individuals by specific CTL which lyse EBV-
infected B-cells upon recognition of viral peptides pre-
sented on the cell membrane in association with
MHC class I molecules.
EBV-specific CTL have been isolated from normal
donor leucocytes and  expanded ex vivo by Rooney et
al.152 Following the reinfusion of 1.23108 CTL/m2
into an allograft recipient, the complete resolution
of an EBV-related immunoblastic lymphoma was
observed.
Ex vivo expanded CTL can also be used to restore
CMV-specific responses in immunodeficient individ-
uals receiving allogeneic BMT. Walter et al.153 treated
14 patients with infusions of CD8+ CTL directed to
CMV proteins obtained from bone marrow donors.
In this study, CMV-specific CTL were expanded by
stimulation with anti-CD3 antibodies coupled with
autologous CMV-infected fibroblasts in IL-2-con-
taining culture. This approach to adoptive immuno-
therapy was well tolerated by the recipients and not
associated with severe GVHD.
Future directions
Preliminary clinical data suggest that the efficacy of
donor BC infusion for the treatment of leukemic
relapse can be significantly improved by the adminis-
tration of IL-2 in vivo after reinfusion and by a brief
incubation of BC with IL-2 before the reinfusion.154
The antitumor efficacy of T-lymphocytes can also be
enhanced by transfection of cytokine genes or new
receptors. An interesting approach is represented by
the binding of TCR to a specific anti-tumor antibody
Fab fragment or the use of bispecific (anti-tumor and
anti-CD3) antibodies capable of recruiting and
expanding tumor-specific CTL at the tumor site.155
Recently, a significant autologous GVHD effect has
been obtained by the addition of g-IFN to cyclo-
sporin-A in order to upregulate MHC class II mole-
cules .113 Alternatively, GM-CSF seems to enhance the
anti-tumor response by stimulating professional APC
(see below).156
In conclusion, there is clear evidence that CTL exert
their cytotoxic effect through the recognition of
minor HLA antigens.157 However, in some patients  a
very low frequency of specific antileukemic CTL,
responsible for a GVL effect distinct from GVHD,
have been isolated. Moreover, genetic approaches,
such as the transduction of donor lymphocytes with
a suicide gene, have been proposed to control GVHD
occurring after CTL administration.158
Ex vivo generation of human dendritic APC
Clinical investigators are keenly interested in the
role of APC in the initiation of immune responses
because of the potential to exploit these cells for
immunotherapy of cancer and viral diseases. Pioneer
studies in mammals by Steinman et al.159 have
demonstrated that the specialized system of APC is
constituted by BM-derived dendritic cells (DC). DC
are distinguished by their unique potency and ability
to capture, process, and present antigens into pep-
tide-HLA complexes to naive T lymphocytes and to
deliver the co-stimulatory signals necessary for T lym-
phocyte activation and proliferation.
Here, we summarize the main experimental evi-
dence supporting the working hypothesis that indi-
viduals vaccinated with DC expanded ex vivo and engi-
neered to present tumor associated antigen(s) can
mount tumor-specific humoral and cellular respons-
es. This can lead to tumor regression as well as pro-
tective immunity against tumor growth in vivo.159-162
Identification of dendritic cells
DC are leukocytes derived from hematopoietic stem
cells along the myeloid differentiation pathway (Figure
5). The differentiation of DC is a stepwise process:163
originating from myeloid progenitors in the BM, imma-
ture DC distribute via blood to tissues where they have
the capacity to take up and to process antigens. As
migratory DC, they transit through the lymph or blood
to lymphoid organs, where they become mature DC,
which lose antigen-processing ability and acquire supe-
rior antigen-presenting capacity for T lymphocytes.163
In humans, DC at different developmental stages cir-
culate in PB and they are found in virtually all tissues
of the body where, depending on the location, they are
referred to as interstitial DC (heart, kidney, gut, and
lung), Langerhans cells (skin, mucous membranes), inter-
digitating DC (thymic medulla, secondary lymphoid tis-
sue); or veiled cells (lymph, blood).163 DC are regarded
as distinct from monocytes/macrophages, although
they share a common progenitor after the CFU-GM
stage. However, this has been questioned as mixed
colonies of dendritic cells and macrophages are gen-
erated in vitro from single CD34+ hematopoietic prog-
enitors more commonly163-175 than pure DC colonies.176
DC can be distinguished from other APC by a)
morphology; b) cell-surface membrane phenotype;
and c) the strong capacity to present antigens to T
cells, usually assessed in the allogeneic mixed leuko-
cyte culture (reviewed in ref. #163).
Cutaneous DC, as well as most of the DC generat-
ed ex vivo from human CD34+ progenitors cells express
high levels of the surface membrane CD1a antigen
(Figure 6). Although CD1a antigen can be found on
cortical thymocytes and some B lymphocytes, its pres-
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ence (noted by immunofluorescence and flow cytom-
etry) is the most useful way to quantify the ex vivo gen-
eration of DC from early precursors. In addition to the
CD1a antigen, DC express peculiarly high levels of
class I and class II histocompatibility complex struc-
tures, co-stimulatory molecules for T-lymphocytes
such as B7-1 (CD80) and B7-2 (CD86), and adhesion
molecules such as ICAM-1 (CD54) and ICAM-3
(CD50) which are involved in DC-dependent T-lym-
phocyte proliferation. DC lack monocyte/macro-
phage- and lymphocyte-lineage-restricted antigens
with the exception of the CD4 antigen.170 As shown in
Table 3, relevant co-stimulatory (B7-1 and B7-2) and
adhesion molecules (ICAM-1) are expressed on all
CD1a+ cells derived from CD34+ progenitors, but on
fewer CD1a+ cells derived from monocytes.177,178 More
recently, the CD83 cell surface antigen has been rec-
ognized as a valuable tool for detecting blood DC.179
Ex vivo expansion of dendritic cells
Although DC circulate in the PB and are found in
virtually all tissues of the body, it is difficult  to obtain
enough cells for ex vivo manipulation because of their
scattered locations and low number in the blood
where they account for approximately 0.1% of all
leukocytes.163 For this reason, it has been of crucial
interest to know that: a) TNF-a cooperates with GM-
CSF to generate DC from CD34+ hematopoietic
progenitors  from BM, cord blood or PB;166, 168-176 and
b) IL-4 cooperates with GM-CSF in the development
of DC from circulating monocytes.169,180 A detailed
description of the methods utilized to obtain human
DC from myeloid precursors has been recently report-
ed.163 However, in evaluating these methods in view
of a clinical trial, at least three issues should be tak-
en into consideration:
a) the type of DC generated either from monocytes
(monocyte-derived DCs) or from CD34+ hemato-
poietic progenitors (CD34+ derived DC);
b) the source of serum for DC growth in culture;
c) the combination of cytokines required for opti-
mal ex vivo expansion of functional immunostim-
ulatory DC.
Monocyte-derived DC are being employed in
patients with advanced stage malignancies in phase I-
II clinical trials. The trials are particularly aimed at eval-
uating toxicity and immune responses after subcuta-
neous administration following DC pulsing ex vivo with
either melanoma tumor-associated peptides181-183 or
with B-cell lymphoma and myeloma idiotype proteins
from autologous serum.151,161 Early reports from clin-
ical studies, in patients with melanoma who are HLA-
A1 positive and whose malignant cells express the
MAGE-1 gene, show that in vivo immunization with
autologous monocyte-derived DC pulsed with MAGE-
1 gene coded nonapeptide, is not toxic and can
induce peptide-specific autologous melanoma reac-
tive CD8+ cytotoxic T-lymphocyte responses in situ at
the vaccination site and at distant tumor sites181 as
well as in PB.182 From a technical point of view, in
these studies the generation of DC from PB mononu-
clear cells is dependent on a culture medium neces-
sarily containing GM-CSF without serum or with
human pooled donor serum. Under these conditions
the production of DC is quite scarce in comparison
with that achieved with fetal calf serum, as reported
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Figure 5. Scheme of DC
development in BM, PB
and thymus. 
Abbreviations: ly,  lympho-
cyte; NK, natural killer
cells; NSE, non-specific
esterase; PPSC,  pluripo-
tent stem cells; CFU-DL,
dendritic/Langherans cell
colony  forming unit. Modi-
fied from Reid CA, Br J
Haematol  1997; 96:217-
33.
Clinical use of hematopoietic stem cells 839
in early studies.169 However, the presence of fetal calf
serum in the culture medium induces undesired DC-
mediated immune responses to xenogenic proteins as
observed in murine184 and human preclinical stud-
ies.170 In this regard, experimental data suggest that
CD34+ cell-derived DC can also be generated in the
absence of serum if the culture medium containing
GM-CSF and TNF-a is supplemented with TGF-b1.185
Modalities for the large-scale procurement of func-
tional DC from CD34+ hematopoietic progenitors in
patients with cancer have been evaluated.170 It was
found that mobilized PB progenitors currently utilized
in phase III trials186 include a fraction of CD34+ DC
precursors which give origin ex vivo to a progeny with
the characteristics of professional APC i.e., typical DC
morphology and immunophenotype undistinguish-
able from cutaneous Langerhans cells and DC from
cord blood and BM CD34+ cells. Most importantly,
these ex vivo generated DC retained the capacity to
process and present antigens to T lymphocytes as
demonstrated by elicitation of HLA class II and class
I-restricted activation of CD4+ and CD8+ autologous
T lymphocytes in response to xenogenic antigens of
fetal calf serum170 or melanoma tumor-associated
antigen peptides,177, 178 respectively. Quantification of
progenitors of DC by limiting dilution analysis of
CD34+ cells sorted from blood cell autografts showed
that they are approximately 140-fold more numerous
than in steady-state control autograft. To obtain this
favorable result, blood cell autografts were collected
at the time of maximal mobilization of CD34+ cells
into PB as occurs after treatment with high-dose
cyclophosphamide and cytokines.
In a systematic search for culture conditions capa-
ble of ameliorating the ex vivo generation of DC den-
dritic cells, a variety of exogenous stimuli have been
evaluated as well as monocyte-derived versus CD34+
cell-derived DC.170,177,178 In this respect, it has been
shown that GM-CSF plus TNF-a-dependent genera-
tion of DC from mobilized CD34+ cells is 2.5 fold
enhanced by either FL or SCF, and 5-fold enhanced by
a combination of these growth factors. In addition,
autologous high-dose chemotherapy recovery phase
serum rather than fetal calf serum or human donor
pooled AB serum has been shown to be the optimal
serum for the generation of DC. Regardless of the pre-
cise mechanism of action of FL and SCF in association
with GM-CSF and TNF-a on the enhancement of DC
Table 3. Phenotype of CD1a+ dendritic cells generated from
mobilized CD34+ progenitors or from monocytes.
CD1a+ cells derived from
Antigens CD34+ progenitors Monocytes
CD14 2% 3%
CD80 100% 84%
CD86 100% 67%
CD54 100% 67%
MHC Class I
HLA-A0201 100% 100%
MHC Class II
HLA-DR 100% 100%
HLADQ 60% 89%
Modified from Mortarini et al., Cancer Res, in press.
Figure 6. Flow cytometry evaluation of cell surface phenotype of DC derived ex vivo from CD34+ progenitors on day 12 of cul-
ture in the presence of GM-CSF, TNF-a, SCF and FL.
differentiation and proliferation, these findings have
provided new advantageous tools for the large-scale
generation of DC from mobilized CD34+ cells in
patients undergoing cancer treatment. In fact, the
stimulation of CD34+ cells from an average blood cell
autograft should permit the generation of a median of
0.63109/kg DC from an average 65 kg individual, i.e.,
almost 403109 DC. In contrast, differentiation of DC
from monocytes in the presence of autologous high-
dose chemotherapy recovery phase serum plus GM-
CSF and IL-4 is not associated with a comparably high
outgrowth of DC.177,178 These observations, together
with the weaker expression of co-stimulatory mole-
cules in monocyte-derived DC in comparison with
CD34+ cell-derived DC187 may favor the utilization of
the latter source of APC for the development of active
immunization programs involving DC in humans. The
comparative efficiency as APC of DC derived from
monocytes versus CD34+ hematopoietic progenitors
has recently been studied with DC isolated from blood
of patients with melanoma. In particular, it has been
shown that DC derived from G-CSF-mobilized CD34+
cells are more efficient than those derived from mono-
cytes in inducing melanoma tumor-associated anti-
gen peptide specific activation of autologous CD8+
cytotoxic T-lymphocytes. Interestingly, in the same
experiments the latter cells were also capable of lysing
a panel of melanoma cell lines sharing the same HLA
class I alleles with the patients from whom CD8+ cyto-
toxic T-lymphocytes were generated with tumor-asso-
ciated antigen peptide pulsed autologous DC.177,178
Moreover, CD34+ cells mobilized into PB by G-CSF
were shown to be capable of generating a higher num-
ber of mature and fully functional DC than their BM
counterparts.188 However, it should be pointed out
that, at  present, clinical studies utilizing DC as vehi-
cles for anti-tumor vaccination have been carried out
with monocyte-derived DC either freshly isolated from
PB152 or cultured ex vivo.161, 181-183 In addition, culture
conditions which allow the large scale production of
terminally differentiated and fully functional mono-
cyte-derived DC have recently been described.189
Dendritic cells for antitumor cell therapy
An extensive review on the clinical use of DC is
beyond the scope of this paper, however, a few
remarks in this regard are needed. 
The goal of vaccination is the induction of protec-
tive immunity. Originally, vaccinations were used in
the setting of infectious diseases, but are now expand-
ing to include the treatment of allergy, autoimmune
diseases, and tumors. A rational approach to vacci-
nation involves 3 steps: a) the identification of the
protective effector mechanisms, b) the choice of an
antigen that can induce a response in all individuals,
and c) the use of an appropriate way to deliver the
vaccine to induce the proper type of response.159-162
It has now been demonstrated that certain tumor
cells are antigenic by expressing tumor-associated
antigens that can be recognized by T lymphocytes in
a syngeneic host. However, they are often poorly
immunogenic, at least in part because they lack the
cellular armamentarium for specific T-lymphocyte
recognition, activation, and co-stimulation typical of
APC especially DC.190,191 Different mechanisms may
account for the ability of tumor cells to evade immune
responses. Tumor cells may display low immu-
nogenicity through low MHC and/or tumor-speciifc
antigen expression or may downregulate Fas and con-
stitutively express Fas-Ligand, which binds to Fas on
cytotoxic T-lymphocytes, resulting in apoptosis of the
latter.192 Furthermore, it has recently been shown that
vascular endothelial growth factor produced by
tumors inhibits the functional maturation of CD34+
cell-derived DC.193 When considering the use of the
unique antigen-presenting capacity of DC to prime
specific antitumor T-lymphocytes, this phenomenon
should be taken into account, as it may result in poor
recovery and function of DC directly recovered from
the blood of cancer patients. In contrast, dendritic
APC expanded ex vivo in the presence of cytokines and
in the absence of inhibitory factors released by tumors
would probably be functional.193-195 However, it
should also be considered that published data
demonstrate that whereas in vivo administration of
DC loaded with low doses of tumor antigen enhances
antitumor immunity, DC pulsed with high doses of
antigen or high numbers of tumor antigen-pulsed DC
may inhibit development of immunity.196 This finding
supports the notion that stimulation of DC-mediat-
ed antigen presentation in vivo may act in a tolerogenic
or immunogenic fashion depending on a variety of
partially understood factors.197
Basically, there are at least two approaches to
tumor vaccination (Figure 7). The first is to identify
a tumor-associated antigen to be used as a vaccine,
the second is to increase the immunogenicity of
tumor cells and let the immune system decide which
antigen to target. Indeed, in experimental models
with the appropriate manipulation exploiting the
physiologic function of antigen-presenting DC, the
immune system can be induced to mount responses
that can kill tumor cells and also protect animals
from subsequent challenge even with a poorly immu-
nogenic tumor.185,198-203
Given the richness of recently identified tumor asso-
ciated antigens and their corresponding peptide epi-
topes recognized by MHC-restricted CD8+ or CD4+ T
lymphocytes (Table 4), investigators are currently
evaluating the clinical efficacy of specific tumor-asso-
ciated antigen-based vaccines for the treatment of
various malignancies. Recently, in a cooperative clin-
ical trial it was observed that partial tumor regres-
sions can occur in HLA-A1+ patients with melanoma
treated with a naked MAGE 3 peptide epitope vac-
cine even in the absence of any engineering of anti-
gen-presenting cells or adjuvant cytokine(s).204 This
clinical evidence induces the belief that the effective-
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ness of peptide-based vaccines is likely to benefit fur-
ther from administration of appropriate cyto-
kines156,205,206 or cellular adjuvants (e.g. DC) capable
of promoting cellular immunity.
Among hematologic malignancies, CML is being
intensively evaluated as a possible target of dendrit-
ic APC-based immunotherapy. It is well known that
CML is characterized by a specific translocation of
the c-abl oncogene (9q34) to the bcr region on chro-
mosome 22 (22q11). Alternative recombination sites
involving either the second or third exon of the bcr
gene splicing to exon 2 of the abl gene yield two
potential fusion gene transcripts, b2a2 and b3a2,
respectively. The translated 210-kd bcr-abl fusion pro-
tein, which has abnormal tyrosine kinase activity,
includes a new potentially antigenic sequence at the
fusion site: a new amino acid is generated at the junc-
tional site by the fusion event; in the b2a2 fusion a
glutamic acid (E) is encoded, whereas in the b3a2
recombination event a lysine (K) is generated. Inter-
estingly, a bcr-abl peptide from the b3a2 fusion region
has been found to be immunogenic in mice.207 In
humans, binding of b3a2 peptides to various HLA
class I alleles208 and priming of CD8+ cytotoxic T-lym-
phocytes in vitro has been described although the
capacity of these peptide-specific CD8+ T-lympho-
cytes to lyse CML cells has not been determined.209 In
contrast, in a recent study it has been demonstrated
that CD4+ T-lymphocytes can be identified that pro-
liferate in an HLA class-II restricted manner in
response to a 11mer (GFKQSSKALQR) b3a2 peptide
especially when the latter is presented by purified
CMRF-44+ blood DC.210 In the same study the pep-
tide-specific CD4+ T-lymphocytes were able to
respond to the whole protein in crude extract from
CML cells. Intriguingly, dendritic antigen-presenting
cells in CML patients can be derived from the malig-
nant clone and these malignant dendritic cells can
induce antileukemic reactivity in autologous T lym-
phocytes without  the necessity of additional exoge-
nous antigens.211
Although, the above observations cannot be extra-
polated a priori to other malignancies carrying specific
translocations and corresponding fusion genes and
products,212 further investigations on the possible
clinical application of bcr-abl peptide(s) presented by
autologous dendritic antigen-presenting cells are
warranted.
The translation into the clinical setting of the above
experimental hints favoring the use of DC pulsed ex
vivo with synthetic tumor-associated antigen peptides
for effective cell therapy in humans is likely to be ham-
pered by: a) the limited availability of patients with
HLA typing compatible for the utilized tumor-asso-
ciated antigen peptide(s); b) the occurrence of inde-
pendent mechanisms of tumor escape in vivo such as
loss of expression of tumor-associated antigens or of
HLA class I during tumor progression; and c) the
short duration of the immune responses thus requir-
ing annoying boost vaccinations. It has been sug-
gested213 that these limitations may be overcome by
transduction of genes encoding relevant proteins into
DC or their progenitors so that DC could tailor pep-
tides to their own HLA molecules thus obviating the
need to synthesize tumor-specific peptides most of
which have stringent HLA restrictions. A further
advantage of the transduction approach may be the
stable long-term expression of the antigen by the DC,
which would allow its presentation to the immune
system for longer periods without the concerns about
the turnover of preformed peptide/HLA complexes
in vivo after immunization.214
Based on the above experimental body of evidence,
a pioneer clinical trial has evaluated the ability of
autologous monocyte-derived DC pulsed ex vivo with
non Hodgkin’s lymphoma-specific idiotype protein
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Figure 7. Sources of tumor anti-
gens for DC-based cancer vaccines.
to stimulate host immunity when infused as a vac-
cine.151 In this study active immunotherapy of patients
with B-cell lymphoma against idiotypic determinants
led to anti-tumor immunity that correlated with
improved clinical outcome in some patients.
Regardless of the type of cell manipulation (Figure
7) (ex vivo pulse with tumor-associated antigen pep-
tides versus transduction with tumor associated anti-
gen genes versus immunization with fusions of den-
dritic and carcinoma cells215) that will be successful
in clinical applications  the necessity of methods of
generating large numbers of functional DC is implic-
it for the evolution of such studies.
Future directions
Since DC have been shown to be intimately involved
in the generation of CD4+ and CD8+ T-lymphocyte
mediated tumor-specific immunity, it is attractive to
speculate that vaccination with DC pulsed or engi-
neered ex vivo to present tumor antigen(s) may be
effective in generating tumor immunity in vivo. Among
the recently prospected sources of DC, namely BM,
neonatal cord blood, and adult PB, the last is cer-
tainly the richest and most accessible in all patients
with cancer, although it remains to be confirmed
whether functional differences will favor the utiliza-
tion of monocyte- versus CD34+ cell-derived DC.
Thus, in the clinical setting of adoptive immunother-
apy for patients with malignancies, a therapeutic pro-
tocol could be envisioned involving the mobilization
of CD34+ cells into PB with hematopoietic growth
factors, with or without prior intensive chemotherapy.
Thus, enrichment of hematopoietic progenitor cells
could be followed by ex vivo generation of DC pulsed
or engineered to present tumor antigen(s), to be rein-
fused as a potential secondary tumor-specific immu-
notherapy or vaccination. It remains to be established
whether the latter effect could be further enhanced
by in vivo adjuvant cytokines such as GM-CSF and/or
FL, as occurs in murine models.
A potential advantage of ex vivo immune cell thera-
py over direct in vivo immune intervention, is the lack
of functional inhibition that may occur in vivo. This
hypothesis is based on a recently proposed  mecha-
nism of tumor escape/resistance from the host
immune system, in which cancer cells produce a vas-
cular endothelial growth factor that impairs antigen
presentation required to induce specific antitumor
immune responses in vivo.193
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